Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial

IMPORTANCE: Fewer than 50% of kidney transplant recipients (KTRs) develop antibodies against the SARS-CoV-2 spike protein after 2 doses of an mRNA vaccine. Preliminary data suggest that a heterologous vaccination, combining mRNA and viral vector vaccines, may increase immunogenicity. OBJECTIVE: To a...

Descripción completa

Detalles Bibliográficos
Autores principales: Reindl-Schwaighofer, Roman, Heinzel, Andreas, Mayrdorfer, Manuel, Jabbour, Rhea, Hofbauer, Thomas M., Merrelaar, Anne, Eder, Michael, Regele, Florina, Doberer, Konstantin, Spechtl, Paul, Aschauer, Constantin, Koblischke, Maximilian, Paschen, Christopher, Eskandary, Farsad, Hu, Karin, Öhler, Barbara, Bhandal, Arshdeep, Kleibenböck, Sabine, Jagoditsch, Rahel I., Reiskopf, Bianca, Heger, Florian, Bond, Gregor, Böhmig, Georg A., Strassl, Robert, Weseslindtner, Lukas, Indra, Alexander, Aberle, Judith H., Binder, Michael, Oberbauer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689434/
https://www.ncbi.nlm.nih.gov/pubmed/34928302
http://dx.doi.org/10.1001/jamainternmed.2021.7372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689434/
https://www.ncbi.nlm.nih.gov/pubmed/34928302
http://dx.doi.org/10.1001/jamainternmed.2021.7372

Ejemplares similares